glp-1 optimization Optimizing therapies for obesity and diabetes management Key Benefits The Surprising Truth About Nutrition

The SELECT study: a warning In 2023, semaglutide was shown to reduce the rates of major adverse cardiovascular events by 20% among persons with a history of atherosclerotic cardiovascular disease and obesity or in persons with overweight and one or more weight-related complications [79]

Addressing underlying conditions: Treatment should target identified respiratory or cardiovascular conditions

The key findings include: 9 total patients (mean age 57.4 years, range 37-77 years) developed significant vision complications

Klass referred Eric to Dr

Safe Titration and Monitoring: Both medications require a gradual increase in dosage (titration) over several weeks or months to minimize common, temporary side effects like nausea, vomiting, and digestive issues